Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Ostridge

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|March 9, 2026
Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework RecommendationEmuella Flood, Niklas Karlsson, Jennifer Ostridge, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2024
Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)Naim Shehadeh, Pietro Galassetti, Nayyar Iqbal, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|March 9, 2026
Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework RecommendationEmuella Flood, Niklas Karlsson, Jennifer Ostridge, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2024
Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)Naim Shehadeh, Pietro Galassetti, Nayyar Iqbal, et al.
Pageof 1